Comparative Pharmacology
Head-to-head clinical analysis: LEQSELVI versus TZ 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEQSELVI versus TZ 3.
LEQSELVI vs TZ-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LEQSELVI is a selective estrogen receptor degrader (SERD) that binds to estrogen receptors (ER), inducing their degradation and blocking ER-mediated signaling.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
LEQSELVI is not a recognized pharmaceutical name. No dosing information available.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours in healthy adults; may be prolonged in patients with moderate to severe hepatic impairment.
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Primarily excreted as unchanged drug via renal elimination (approximately 70% of dose), with biliary/fecal excretion accounting for about 20%.
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Category C
Category C
Unknown
Unknown